Article

Increase in intracellular PGE2 induces apoptosis in Bax-expressing colon cancer cell. BMC Cancer 11:153

Département de Biologie Oncologique, Centre de Lutte Contre le Cancer René Gauducheau, Bd J, Monod, 44805 Nantes, Saint Herblain Cedex, France.
BMC Cancer (Impact Factor: 3.36). 04/2011; 11(1):153. DOI: 10.1186/1471-2407-11-153
Source: PubMed

ABSTRACT

NSAIDs exhibit protective properties towards some cancers, especially colon cancer. Yet, it is not clear how they play their protective role. PGE2 is generally shown as the only target of the NSAIDs anticancerous activity. However, PGE2 known targets become more and more manifold, considering both the molecular pathways involved and the target cells in the tumour. The role of PGE2 in tumour progression thus appears complex and multipurpose.
To gain understanding into the role of PGE2 in colon cancer, we focused on the activity of PGE2 in apoptosis in colon cancer cell lines.
We observed that an increase in intracellular PGE2 induced an apoptotic cell death, which was dependent on the expression of the proapoptotic protein Bax. This increase was induced by increasing PGE2 intracellular concentration, either by PGE2 microinjection or by the pharmacological inhibition of PGE2 exportation and enzymatic degradation.
We present here a new sight onto PGE2 in colon cancer cells opening the way to a new prospective therapeutic strategy in cancer, alternative to NSAIDs.

Download full-text

Full-text

Available from: Lisenn Lalier
  • Source
    • "In mitochondria mediated apoptotic cell death process Bax acts as an essential gatekeeper as its activation irreversibly commits the most of the cells to die [40,41]. It has been studied extensively on its relationship with different types of cancer, such as  pancreatic [19,42], bladder [21], gastric [18], colorectal [43,44], esophageal [16], lung [32,45,46], cervical [47], colon [48,49], prostate carcinoma [50,51], squamous cell carcinoma of the head and neck [36], nasopharyngeal carcinoma [52], breast carcinomas [32,53], ovarian carcinoma [54], renal and transitional cell cancer [55], gliomas [56], CLL [30,31,33–35,38,57], Hodgkin’s lymphoma [17], non-Hodgkin's lymphoma [58], myeloma [59], acute leukemia [60], etc. Bax promoter contains response elements for an important tumor suppressor p53 and this affects gene expression [28]. With respect to the important roles of Bax in apoptosis, it is biologically plausible that its polymorphism may modulate the risk of cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Bcl-2-associated X protein (Bax) is a proapoptotic member of the Bcl-2 family known to be activated and upregulated during apoptosis. Single nucleotide polymorphisms (SNPs) in Bax promoter may participate in the process of carcinogenesis by altering its own expression and the cancer related genes. Bax-248G>A polymorphism has been implicated to alter the risk of cancer, but the listed results are inconsistent and inconclusive. In the present study, we performed a meta-analysis to systematically summarize the possible association of this polymorphism with the risk of cancer.
    Full-text · Article · Oct 2013 · PLoS ONE
  • Source
    • "First, as has been previously shown, PG can stimulate programmed cell death by inducing the pro-apoptotic protein Bax (Lalier et al. 2011); second, VEGF acting in synergy would most likely further enhance apoptosis. In addition, tryptophan is an amino acid that is essential to cell survival and IDO activation reduces its availability to the cell (Broker et al. 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dendritic cells (DCs) are antigen (Ag)-presenting cells that activate and stimulate effective immune responses by T cells, but can also act as negative regulators of these responses and thus play important roles in immune regulation. Pro-angiogenic vascular endothelial growth factor (VEGF) has been shown to cause defective DC differentiation and maturation. Previous studies have demonstrated that the addition of VEGF to DC cultures renders these cells weak stimulators of Ag-specific T cells due to the inhibitory effects mediated by VEGF receptor 1 (VEGFR1) and/or VEGFR2 signalling. As the enzyme indoleamine 2,3-dioxygenase (IDO) is recognised as an important negative regulator of immune responses, this study aimed to investigate whether VEGF affects the expression of IDO by DCs and whether VEGF-matured DCs acquire a suppressor phenotype. Our results are the first to demonstrate that VEGF increases the expression and activity of IDO in DCs, which has a suppressive effect on Ag-specific and mitogen-stimulated lymphocyte proliferation. These mechanisms have broad implications for the study of immunological responses and tolerance under conditions as diverse as cancer, graft rejection and autoimmunity.
    Full-text · Article · Oct 2013 · Memórias do Instituto Oswaldo Cruz
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A number of studies, including our own, have indicated the involvement of inflammatory and autoimmune reactions in the pathogenesis of schizophrenia (SCZ). Earlier, we revealed the presence of type III cryoglobulins (Cgs), indicators of autoimmunity and inflammation, in the blood of patients with SCZ and found the presence of complement activation split products in these complexes. Accounting for a vascular-inflammatory theory of SCZ and the ability of Cgs to cause immune complex vacuities and activate the inflammatory response, we propose that in SCZ Cgs may not only represent non-specific markers of upregulated immune response, but also have direct implication in etiopathomechanisms of this disease. In the present study we investigated the effects of Cgs isolated from the blood of SCZ patients on human peripheral blood mononuclear cells (PBMCs) in vitro. According to the data obtained, Cgs induce monocyte chemoattractant protein-1 (MCP-1) production by PBMCs. The results obtained suggest that Cgs participate in SCZ-associated inflammatory reactions. Keywords: cryoglobulins, monocyte chemoattractant protein-1, peripheral blood mononuclear cells, schizophrenia.
    Full-text · Conference Paper · Jan 2012
Show more